PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company’s pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio’s proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities. 

Looking for a new role? Please visit our careers page to find out more about our open jobs and benefits at https://phasebio.com/careers/

SFJ Pharmaceuticals

AstraZeneca

Hatteras Venture Partners

Syno Capital

Cormorant Asset Management

Fletcher Spaght, Inc.

Rock Springs Capital

Johnson & Johnson Innovation – JJDC

Mountain Group Capital

New Enterprise Associates

PhaseBio Pharmaceuticals, Inc.

DNSSEC

reCAPTCHA

Gravity Forms

Akamai Hosted

Verizon

Verizon FIOS

Owner

Finn Ben

Chief Medical Officer

John Lee

Chief Financial Officer

John Sharp

Chief Commercial Officer

Jonathan Birchall

Senior Vice President & General Counsel

Kris Hanson

Robert Villarreal

Senior Vice President, Head of Human Resources

Glen Burkhardt

Vice President, Research & Scientific Affairs

Jim Ballance

Sales and Support

Kamran Mammadov

Associate Director, CMC

Adria Conway

Edmund P. Harrigan

Richard van den Broek

Linda Tufts

Alex Sapir

Ashutosh Chilkoti

Jonathan Mow

Nancy Hutson

Caroline Loewy

Founder & Board Member

John P. Sharp

Christopher Prior

VP, Human Resources

Craig A. Rosen

Executive Chairman & CSO

Joel Sussman

Chief Executive Officer

Susan Arnold

Vice President of Preclinical and Assay Development

Cormorant Asset Management Portfolio Companies

Pharmaceutical Companies With More Than 10 Employees (Top 10K)

Northeastern US Public Companies With Fewer Than 1000 Employees

Northeastern US Medical Device Companies

PhaseBio is a clinical-stage biopharmaceutical company committed to developing new and improved drugs, with an initial focus on endocrine and metabolic disorders and cardiovascular disease. The company uses its proprietary recombinant biopolymers called elastin-like polypeptides (ELPs) to improve the stability, bioavailability, activity, and ease of administration of proteins and peptides, with the goal of achieving greater potency, fewer side effects, and better patient compliance. Efficient production in E. coli ensures a low cost of goods.

PhaseBio’s lead drug candidate, PB1023, is currently being evaluated in a phase 2b clinical trial for the treatment of hyperglycemia associated with type 2 diabetes, with potential for future use in the treatment of obesity. Our second drug candidate, Vasomera, is currently being evaluated in phase 1 clinical trial and has exciting potential for use in the treatment of pulmonary arterial hypertension (PAH) and heart failure. Its third program, Insumera, basal insulin based on native human insulin, will enter clinical trials in early 2013.

PhaseBio is based in Malvern, Pennsylvania.

Post-IPO Equity - PhaseBio Pharmaceuticals

Series D - PhaseBio Pharmaceuticals

National Institutes of Health

Grant - PhaseBio Pharmaceuticals

Silicon Valley Bank

Debt Financing - PhaseBio Pharmaceuticals

Series C - PhaseBio Pharmaceuticals

Series B - PhaseBio Pharmaceuticals

OSI Pharmaceuticals

Venture Round - PhaseBio Pharmaceuticals

Malvern

Pennsylvania

United States

North America

PhaseBio Pharmaceuticals

PhaseBio announces bankruptcy plan confirmation

Pharma Co. PhaseBio Can Exit Ch. 11 With Wind-Down Plan

Cash from financing activities of PhaseBio Pharmaceuticals, Inc. – OTC:PHASQ – TradingView

Total liabilities & shareholders' equities of PhaseBio Pharmaceuticals, Inc. – OTC:PHASQ – TradingView

Achondroplasia Treatment Drug Market to Register Positive ...

Ocular Hypertension Market Size and Share to Increase by ...

metalloenzyme inhibitor compounds

Short Volatility Alert: PhaseBio Pharmaceuticals, Inc.

Pharmacokinetic &amp; pharmacodynamic model for determining effective dose of anti- …

PhaseBio Pharmaceuticals Announces Bentracimab Manufacturing Update

HTML5

Lightbox

GoDaddy Premium DNS

Microsoft Outlook

Wordpress

Google Analytics

Modernizr

Apache Server

Office 365

Acer is a biopharmaceutical company focused on the development and commercialization of therapies for serious rare and life-threatening diseases.

Acer

Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for liver diseases and immune modulating therapies.

Altimmune

Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing, and delivering high-quality medicines for people living with rare metabolic diseases.

Amicus Therapeutics

Aphios Corporation is a biotechnology company engaged in the discovery and development of therapeutics for the treatment of cancer, infectious diseases, and CNS disorders.

Aphios

Bird Rock Bio is a biotechnology company focused on developing innovative therapies for serious and rare diseases with high unmet medical needs.

Bird Rock Bio

Catalyst Biosciences is a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications.

Catalyst Biosciences

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III clinical trials. The company is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

news impact assignment basic	general	Feb 21, 2024 5:11 PM	7ca751b3
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Feb 21, 2024 5:11 PM	4f284c6a
company summary	general
signals	general
crunchbase trigger	general	Oct 30, 2024 1:02 PM	43781eca
crunchbase profile	general	Oct 30, 2024 11:11 PM	101e4dfe
li profile	general	Feb 21, 2024 5:11 PM	9623e933
translate crunchbase fundingrounds	general	Nov 6, 2024 3:12 PM	61765c33
peers	general	Feb 21, 2024 5:11 PM	dbf36ff8
news basic	general	Feb 21, 2024 5:11 PM	8b829056
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:PHASEBIO

PhaseBio Pharmaceuticals, Inc.

Last Close

0.07

17/09 20:00

Volume Today

8.56M

Avg: -